Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...

Maternal mortality rates in the US remain high, especially compared with those of similarly wealthy countries, despite ...

The FDA has communicated to Stealth BioTherapeutics that it would not meet elamipretide’s PDUFA target date for the treatment of Barth syndrome.

The HHS and the FDA have released further details of their plans to remove all petroleum-based synthetic dyes from the nation's food supply.